Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Pharm Res. 2013 Feb 1;30(5):1447–1457. doi: 10.1007/s11095-013-0986-7

Figure 3. Reduction of hepatic and plasma lipid levels by GW4064 treatment in HFD-induced obese mice.

Figure 3

(A-C) Triglyceride, free fatty acid and cholesterol content in the liver; (D-F) Serum levels of triglyceride, free fatty acid and cholesterol after 6-week treatment. Each data point represents the average ± SD of 4 animals in each group. *P<0.05, **P<0.01 compared to DMSO-treated groups